Sino Biopharmaceutical Limited
1177
Classificação em ações
#1796
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Preço da ação
$0.67161271
Última sincronização: 2026-10-16
Valor de mercado
$11.96B
Variação (1 dia)
-0.38%
Variação (1 ano)
-28.30%
País
HK
Negociar Sino Biopharmaceutical Limited (1177)
Categoria
Healthcare
Margem Operacional de Sino Biopharmaceutical Limited (1177)
Margem Operacional em October 2026 TTM: 29.76%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Sino Biopharmaceutical Limited, a margem operacional atual (TTM) é 29.76%. No final de 2023, a margem operacional era 22.08%.
Histórico da Margem Operacional da Sino Biopharmaceutical Limited de 2000 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2026 (TTM) | 29.76% | 39.98% |
| 2024 | 21.26% | -3.71% |
| 2023 | 22.08% | 2.89% |
| 2022 | 21.46% | 13.48% |
| 2021 | 18.91% | 6.66% |
| 2020 | 17.73% | -26.03% |
| 2019 | 23.97% | 0.67% |
| 2018 | 23.81% | -15.48% |
| 2017 | 28.17% | -15.33% |
| 2016 | 33.27% | 51.36% |
| 2015 | 21.98% | 8.49% |
| 2014 | 20.26% | -28.59% |
| 2013 | 28.37% | 31.46% |
| 2012 | 21.58% | 23.88% |
| 2011 | 17.42% | -34.98% |
| 2010 | 26.79% | 8.46% |
| 2009 | 24.70% | -7.49% |
| 2008 | 26.70% | -21.98% |
| 2007 | 34.22% | 5.72% |
| 2006 | 32.37% | 60.01% |
| 2005 | 20.23% | -20.07% |
| 2004 | 25.31% | 24.19% |
| 2003 | 20.38% | 3.19% |
| 2002 | 19.75% | -10.79% |
| 2001 | 22.14% | -1.29% |
| 2000 | 22.43% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 62.34% | -97.91% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.97% |
US
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.